KBC Group’s Krystal Biotech KRYS Stock Holding History
Bought
Maintained
Sold
Other funds holding KRYS
KBC Group's KRYS Position: Q3 2026 in Review
KBC Group held its Krystal Biotech (KRYS) position steady in Q3 2026 at 685 shares worth $228K. The position accounts for ﹤0.01% of the portfolio, ranked #972.
KBC Group first reported a position in KRYS in Q4 2017 and has held it in 29 quarters since. The position peaked at $255K in Q2 2026. 442 funds tracked by Wall St. Rank hold KRYS as of Q3 2026.
- KBC Group held 685 shares of Krystal Biotech worth $228K as of Q3 2026.
- KBC Group left its Krystal Biotech share count unchanged in Q3 2026.
- Krystal Biotech made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #972 holding.
- KBC Group first reported a position in Krystal Biotech in Q4 2017 and has held it in 29 quarters since.
- KBC Group's Krystal Biotech position peaked at $255K in Q2 2026.
- 442 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2026.
Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.